TABLE 2.
Updates on previously reported nanoparticle clinical trials that are not clinically approved or authorized and are currently active in clinical trials
| Name (company) | Particle type | Payload | Investigated application/indication | ClinicalTrials.gov identifiers (phase) | Updates since 2019 |
|---|---|---|---|---|---|
| Lipid‐based (cancer) | |||||
|
PROMITIL (Lipomedix Pharmaceuticals) |
PEGylated liposome | Mitomycin‐C | Solid tumors |
2016: NCT01705002 (Ph I): Completed 2019: NCT03823989 (Ph Ib): Recruiting (Active as of 2021) 2021 additions: NCT04729205 (Ph I): Recruiting |
2021: One new trial One trial updated to active 2019: One new trial One trial updated to completed |
|
ThermoDox® (Celsion) |
Lyso‐thermosensitive liposome | Doxorubicin | Various cancers |
2016: NCT02536183 (Ph I): Recruiting NCT00826085 (Ph I/II): Completed NCT02112656 (Ph III): Completed NCT02181075 (Ph I): Completed 2019 additions: NCT03749850 (Ph I): Not yet recruiting (Recruiting as of 2021) 2021 additions: NCT04852367 (Ph I): Not yet recruiting NCT04791228 (Ph II): Not yet recruiting |
2021: Two new trials One trial updated to recruiting 2019: One new trial Three trials updated to completed |
|
Oncoprex/GPX‐001 (Genprex) |
Liposome | FUS1 (TUSC2) | Lung cancer |
2016: NCT01455389 (Ph I/II): Active, not recruiting 2021 additions: NCT04486833 (Ph I/II): Not yet recruiting |
2021: One new trial 2019: No updates |
|
Halaven E7389‐LF (Eisai) |
Liposome | Eribulin mesylate | Solid tumors |
2016: NCT01945710 (Ph I): Completed 2019 additions: NCT03207672 (Ph I): Recruiting (Active as of 2021) 2021 additions: NCT04078295 (Ph I/II): Recruiting |
2021: One new trial One trial updated to recruiting Results posted and viewable on ClinicalTrials.gov for NCT01945710 2019: One new trial One trial updated to completed |
| 188Re‐BMEDA‐liposome | Pegylated liposome | 188Re‐N,N‐bis (2‐mercaptoethyl)‐N′,N′‐diethylethylenediamine | Advanced solid tumors |
2016: NCT02271516 (Ph I): Unknown (Terminated as of 2021 due to concerns of accumulation of radioactivity in both the liver and spleen) |
2021: One trial updated to terminated 2019: Zero new trials |
|
Mitoxantrone Hydrochloride Liposome (CSPC ZhongQi Pharmaceutical Technology) |
Liposome | Mitoxantrone | Various cancers |
2016: NCT02131688 (Ph I): Unknown NCT02596373 (Ph II): Recruiting (Unknown status as of 2021) NCT02597387 (Ph II): Recruiting (Unknown status as of 2021) NCT02595242 (Ph I): Withdrawn NCT02597153 (Ph II): Terminated (Only one subject enrolled in 1.5 years) 2019 additions: NCT03776279 (Ph I): Recruiting (Unknown status as of 2021) 2021 additions: NCT04668690 (Ph III): Not yet recruiting NCT04718402 (Ph I): Recruiting NCT04902027 (Ph I): Not yet recruiting NCT04719065 (Ph I): Recruiting NCT04718376 (Ph I): Recruiting NCT04900766 (Ph I): Not yet recruiting NCT04548700 (Ph I): Not yet recruiting NCT04509466 (Ph I): Not yet recruiting NCT04331743 (Ph I): Not yet recruiting NCT04352413 (Ph II): Recruiting |
2021: 10 new trials Three trials updated to unknown status 2019: One new trial One trial updated to withdrawn One trial updated to terminated |
| JVRS‐100 | Cationic liposome | Plasmid DNA complex for immune system stimulation | Leukemia |
2016: NCT00860522 (Ph I): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
Lipocurc (SignPath Pharma) |
Liposome | Curcumin | Solid tumors |
2016: NCT02138955 (Ph I/II): Unknown |
2021: No updates 2019: Zero new trials One trial updated to unknown status |
|
LiPlaCis (LiPlasome Pharma) |
Liposome with specific degradation‐controlled drug release via phospholipase A2 (PLA2) | Cisplatin | Advanced or refractory tumors |
2016: NCT01861496 (Ph I): Recruiting (Active as of 2021) |
2021: One trial updated to active 2019: No updates |
|
MM‐302 (Merrimack Pharmaceuticals) |
HER2‐targeted PEGylated liposome | Doxorubicin | Breast cancer |
2016: NCT01304797 (Ph I): Unknown NCT02213744 (Ph II/III): Terminated (Felt not to show benefit over control per DMC and confirmed via futility analysis) 2019 additions: NCT02735798 (Ph I): Withdrawn (The study was not started due to the sponsor choosing to not fund the trial) |
2021: No updates 2019: One new trial (withdrawn) One trial updated to terminated One trial updated to unknown status |
|
LIPUSU® (Nanjing Luye Sike Pharmaceutical Co., Ltd.) |
Liposome | Paclitaxel | Advanced solid tumors, or gastric, breast cancer |
2016: NCT01994031 (Ph IV): Unknown NCT02142790 (Ph IV): Unknown NCT02163291 (Ph II): Unknown NCT02142010 (Not Provided): Unknown 2019 additions: NCT02996214 (Ph IV): Not yet recruiting (Active as of 2021) |
2021: One trial updated to active 2019: One new trial |
|
TKM‐080301 (Arbutus Biopharma) |
Lipid particle targeting polo‐like kinase 1 (PLK1) | siRNA | Hepatocellular carcinoma |
2016: NCT02191878 (Ph I/II): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
| siRNA‐EphA2‐DOPC | Liposome | siRNA for EphA2 knockdown | Solid tumors |
2016: NCT01591356 (Ph I): Recruiting (Active as of 2021) |
2021: One trial updated to active 2019: Zero new trials |
|
PNT2258 (ProNAi Therapeutics) |
Lipid nanoparticle | Proprietary single‐stranded DNAi (PNT100) | Lymphomas |
2016: NCT02378038 (Ph II): Terminated NCT02226965 (Ph II): Unknown (Completed as of 2021) NCT01733238 (Ph II): Completed |
2021: Results posted and viewable on ClinicalTrials.gov for NCT02378038, NCT02226965, and NCT01733238 2019: Zero new trials One trial updated to completed One trial updated to terminated One trial updated to unknown status |
|
BP1001/Prexigebersen (Bio‐Path Holdings) |
Neutral liposomes | Growth factor receptor bound protein‐2 (Grb‐2) antisense oligonucleotide | Leukemias and solid tumors |
2016: NCT01159028 (Ph I): Active, not recruiting (Updated to completed) 2019 additions: NCT02923986 (Ph I): Recruiting (Withdrawn as of 2021 due to no enrollment) NCT02781883 (Ph II): Recruiting 2021 additions: NCT04196257 (Ph I): Not yet recruiting |
2021: One new trial One trial updated to completed One trial updated to withdrawn 2019: Two new trials |
|
DCR‐MYC (Dicerna Pharmaceuticals) |
Lipid nanoparticle | DsiRNA for NYC oncogene silencing | Solid tumors, multiple myeloma, lymphoma, or hepatocellular carcinoma |
2016: NCT02110563 (Ph I): Terminated (Sponsor Decision) NCT02314052 (Ph I/II) Terminated (Sponsor Decision) |
2021: Results posted and viewable on ClinicalTrials.gov for NCT02314052 2019: Zero new trials Two trials updated to terminated |
|
Atu027 (Silence Therapeutics GmbH) |
Liposome | AtuRNAi for PKN3 knockdown in vascular endothelium | Pancreatic cancer |
2016: NCT01808638 (Ph I/II): Completed |
2021: No updates 2019: Zero new trials One trial completed |
|
SGT‐53 (SynerGene Therapeutics) |
Cationic liposome with anti‐transferrin receptor antibody | Wildtype p53 sequence | Glioblastoma, solid tumors, or pancreatic cancer |
2016: NCT02354547 (Ph I): Recruiting (Active as of 2021) NCT02340156 (Ph II): Recruiting (Terminated as of 2021) NCT00470613 (Ph I): Completed 2019 additions: NCT03554707 (Ph I): Not yet recruiting 2021 additions: NCT02340117 (Ph II): Recruiting |
2021: One new trial Results posted and viewable on ClinicalTrials.gov for NCT02340156 2019: One new trial One trial updated to completed |
|
SGT‐94 (SynerGene Therapeutics) |
Liposome with anti‐transferrin receptor antibody | RB94 plasmid DNA | Solid tumors |
2016: NCT01517464 (Ph I): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
MRX34 (Mirna Therapeutics) |
Liposome | Double‐stranded RNA mimic of miR‐34 |
Liver cancer |
2016: NCT01829971 (Ph I): Terminated (Five immune related serious adverse events) 2019 additions: NCT02862145 (Ph I): Withdrawn (five immune related serious adverse events in Phase 1 study) |
2021: No updates 2019: One new trial (withdrawn) One trial updated to terminated |
|
TargomiRs (EnGeneIC) |
Anti‐EGFR bispecific antibody minicells (bacteria derived nanoparticles) | miR‐16 based microRNA | Mesothelioma and non‐small cell lung cancer |
2016: NCT02369198 (Ph I): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
MM‐310 (Merrimack Pharmaceuticals) |
Liposome functionalized with antibodies targeted to the EphA2 receptor | Docetaxel | Solid tumors |
2019: NCT03076372 (Ph I): Recruiting (Unknown as of 2021) |
2021: No updates |
|
EGFR(V)‐EDV‐Dox (EnGeneIC) |
Bacterially derived minicell | Doxorubicin | Recurrent glioblastoma |
2019: NCT02766699 (Ph I): Recruiting |
2021: No updates |
|
Alprostadil liposome (CSPC ZhongQi Pharmaceutical Technology) |
Liposome |
Alprostadil | Safety and tolerability |
2019: NCT03669562 (Ph I): Recruiting (Unknown as of 2021) 2021 additions: NCT04197323 (Ph II): Recruiting |
2021: One trial updated to active One trial updated to unknown status |
|
Liposomal Annamycin (Moleculin Biotech) |
Liposome | Annamycin | Acute myeloid leukemia |
2019: NCT03388749 (Ph II): Recruiting NCT03315039 (Ph II): Recruiting (Active as of 2021) 2021 additions: NCT04887298 (Ph I/II): Not yet recruiting |
2021: One new trial One trial updated to active |
|
FF‐10832 (Fujifilm Pharmaceuticals) |
Liposome | Gemcitabine | Advanced solid tumors |
2019: NCT03440450 (Ph I): Recruiting |
2021: No updates |
|
Anti‐EGFR‐IL‐dox (Swiss Group for Clinical Cancer Research; University Hospital, Basel, Switzerland) |
Anti‐EGFR immunoliposome | Doxorubicin |
Advanced triple negative EGFR positive breast cancer High grade gliomas |
2019: NCT02833766 (Ph II): Recruiting (Active as of 2021) NCT03603379 (Ph I): Recruiting (Completed as of 2021) |
2021: One trial updated to active One trial updated to completed |
|
TLD‐1/Talidox (Swiss Group for Clinical Cancer Research) |
Liposome | Doxorubicin | Advanced solid tumors |
2019: NCT03387917 (Ph I): Recruiting |
2021: No updates |
|
NC‐6300 (NanoCarrier) |
Micelle | Epirubicin | Advanced solid tumors or soft tissue sarcoma |
2019: NCT03168061 (Ph II): Recruiting |
2021: No updates |
|
MRT5201 (Translate Bio) |
PEGylated liposomes | mRNA | Ornithine transcarbamylase deficiency |
2019: NCT03767270 (Ph I): Not yet recruiting (Withdrawn as of 2021 due to program discontinuation) |
2021: One trial updated to withdrawn |
|
Lipo‐MERIT (BioNTech SE) |
Liposome | Four naked ribonucleic acid (RNA)‐drug products | Cancer vaccine for advanced melanoma |
2019: NCT02410733 (Ph I): Recruiting (Active as of 2021) |
2021: One trial updated to active |
|
BNT114/IVAC_W_bre1_uID (BioNTech SE) |
Patient‐specific liposome (specificity for antigen‐expression on a patient's tumor) | Complexed RNA | Triple negative breast cancer |
2019: NCT02316457 (Ph I): Recruiting (Active as of 2021) |
2021: One trial updated to active |
| Lipid‐based (other) | |||||
|
ND‐L02‐s0201 (Nitto Denko) |
Lipid nanoparticle conjugated to Vitamin A | siRNA |
Hepatic fibrosis and pulmonary fibrosis |
2016: NCT02227459 (Ph I): Completed 2019 additions: NCT01858935 (Ph I): Completed NCT03241264 (Ph I): Completed NCT03538301 (Ph II): Recruiting |
2021: No updates 2019: Three new trials (two completed) One trial updated to completed |
|
ARB‐001467 TKM‐HBV (Arbutus Biopharma) |
Lipid particle | Three RNAi therapeutics that target three sites on the HBV genome | Hepatitis B |
2016: NCT02631096 (Ph II): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
CAL02 (Combioxin SA) |
Cholesterol liposomes for toxin neutralization | Sphingomyelin | Pneumonia |
2016: NCT02583373 (Ph I): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
Nanocort/Sunpharma1505 (Enceladus in collaboration with Sun Pharma Global) |
PEGylated liposome | Prednisolone | Rheumatoid arthritis and hemodialysis fistula maturation |
2016: NCT02495662 (Ph II): Terminated (Slow inclusion) NCT02534896 (Ph III): Terminated |
2021: No updates 2019: Zero new trials Two trials updated to terminated |
|
RGI‐2001 (Regimmune) |
Liposome | α‐GalCer | Mitigating graft versus host disease following stem cell transplant |
2016: NCT01379209 (Ph I/II): Unknown (Completed as of 2021) 2019 additions: NCT04014790 (Ph II): Not yet recruiting (Recruiting as of 2021) 2021 additions: NCT04473911 (Ph I): Recruiting |
2021: One new trial One trial updated to completed One trial updated to recruiting 2019: One new trial |
| Sonazoid | Lipid shell | F‐butane | Contrast enhanced ultrasound for imaging hepatocellular carcinoma, skeletal muscle perfusion, or for estimating portal hypertension |
2016: NCT00822991 (Not Provided): Recruiting (Unknown status as of 2021) NCT02398266 (Ph II): Unknown NCT02188901 (Not Provided): Completed NCT02489045 (Ph IV): Recruiting (Completed as of 2021) 2021 additions: In 2021, there are 28 total studies |
2021: 28 trials total (11 active trials were added after 2019) 2019: Zero new trials One trial updated to unknown status One trial completed |
|
mRNA‐1944 (Moderna) |
Moderna's proprietary lipid nanoparticle technology | Two mRNAs that encode heavy and light chains of anti‐Chikungunya antibody | Safety, tolerability, pharmacokinetics and pharmacodynamics toward the prevention of Chikungunya virus infection |
2019: NCT03829384 (Ph I): Recruiting (Active as of 2021) |
2021: One trial updated to active |
| Polymeric and micelles (cancer) | |||||
|
AZD2811 (AstraZeneca with BIND Therapeutics) |
BIND therapeutics polymer particle accruing platform | Aurora B kinase inhibitor | Advanced solid tumors |
2016: NCT02579226 (Ph I): Recruiting (Completed as of 2021) 2019 additions: NCT03366675 (Ph II): Terminated (Early detection of the purpose of the study) NCT03217838 (Ph I): Recruiting (Completed as of 2021) 2021 additions: NCT04525391 (Ph II): Recruiting NCT04745689 (Ph II): Recruiting |
2021: Two new trials Two trials updated to completed 2019: Two new trials (one terminated) |
|
BIND‐014 (BIND Therapeutics) |
PSMA targeted (via ACUPA) PEG‐PLGA or PLA–PEG particle | Docetaxel | Prostate, metastatic, non‐small cell lung, cervical, head and neck, or KRAS positive lung cancers |
2016: NCT02479178 (Ph II): Terminated NCT02283320 (Ph II): Completed NCT01812746 (Ph II): Completed NCT01792479 (Ph II): Completed NCT01300533 (Ph I): Completed |
2021: No updates 2019: Zero new trials Four trials updated to completed |
|
Cynviloq IG‐001 (Sorrento) |
Polymeric micelle | Paclitaxel | Breast cancer |
2016: NCT02064829 (Not Provided): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
Genexol‐PM (Samyang Biopharmaceuticals) |
Polymeric micelle | Paclitaxel | Head and neck or breast cancer |
2016: NCT01689194 (Ph II): Unknown (Completed as of 2021) NCT02263495 (Ph II): Completed NCT00912639 (Ph IV): Unknown 2019 additions: NCT02739633 (Ph II): Recruiting (Unknown as of 2021) NCT03008512 (Ph II): Recruiting (Terminated as of 2021, due to poor accrual) |
2021: One trial updated to unknown status One trial updated to terminated 2019: Two new trials One trial updated to completed One trial updated to unknown status |
|
NC‐6004 Nanoplatin (Nanocarrier) |
Polyamino acid and PEG micellar nanoparticle | Cisplatin | Advanced solid tumors, lung, biliary, bladder, or pancreatic cancers |
2016: NCT02240238 (Ph I/II): Active, not recruiting (Completed as of 2021) NCT02043288 (Ph III): Unknown (Completed as of 2021) 2019 additions: NCT03771820 (Ph II): Not yet recruiting (Recruiting as of 2021) NCT03109158 (Ph I): Completed NCT02817113 (Ph I): Unknown (Terminated as of 2021 due to strategy change) |
2021: Two trials updated to completed One trial updated to recruiting One trial updated to terminated 2019: Three new trials One trial updated to unknown status |
|
NC‐4016 DACH‐Platin micelle (Nanocarrier) |
Polyamino acid and PEG micellar nanoparticle | Oxaliplatin | Advanced solid tumors or lymphomas |
2016: NCT01999491 (Ph I): Completed |
2021: No updates 2019: Zero new trials |
|
NK105 (Nippon Kayaku) |
Micelle | Paclitaxel | Breast cancer |
2016: NCT01644890 (Ph III): Completed |
2021: Results posted and viewable on ClinicalTrials.gov for NCT01644890 2019: Zero new trials One trial completed |
|
Docetaxel‐PM DOPNP201 (Samyang Biopharmaceuticals) |
Micelle | Docetaxel | Head and neck cancer and advanced solid tumors |
2016: NCT02639858 (Ph II): Recruiting (Unknown as of 2021) NCT02274610 (Ph I): Completed 2019 additions: NCT03585673 (Ph II): Recruiting (Unknown as of 2021) 2021 additions: NCT04066335: Recruiting |
2021: One new trial Two trials updated to unknown 2019: One new trial One trial updated to completed |
|
CriPec (Cristal Therapeutics) |
Micelle | Docetaxel | Solid tumors, ovarian cancer |
2016: NCT02442531 (Ph I): Completed 2019 additions: NCT03712423 (Ph I): Recruiting (Completed as of 2021) NCT03742713 (Ph II): Recruiting (Completed as of 2021) |
2021: Two trials updated to completed 2019: Two new trials One trial updated to completed |
|
CRLX101 (Cerulean) |
Cyclodextrin based nanoparticle | Camptothecin | Ovarian, renal cell, small cell lung, or rectal cancers |
2016: NCT02187302 (Ph II): Completed NCT02010567 (Ph I/II): Active, not recruiting (Terminated as of 2021 due to funding partner's request) NCT02389985 (Ph I): Terminated (Company decision) NCT01803269 (Ph II): Terminated (Due to lack of activity and slow accrual) NCT01652079 (Ph II): Completed 2019 additions: NCT02769962 (Ph I): Recruiting NCT03531827 (Ph II): Recruiting NCT02648711(Ph I): Terminated (Company decision) NCT01380769 (Ph II): Completed NCT01612546 (Ph II): Completed NCT00333502 (Ph II): Completed NCT01625936 (Ph I): Completed NCT00753740 (Ph II): Withdrawn (Poor trial recruitment) NCT00163319 (Ph III): Completed |
2021: One trial updated to terminated Results posted and viewable on ClinicalTrials.gov for NCT01380769, NCT01803269, and NCT02010567 2019: Nine new trials (one terminated, one withdrawn, five completed) Two trials updated to completed Two trials updated to terminated |
|
CRLX301 (Cerulean) |
Cyclodextrin based nanoparticle | Docetaxel | Dose escalation study in advanced solid tumors |
2016: NCT02380677 (Ph I/II): Terminated (Company decision) |
2021: Results posted and viewable on ClinicalTrials.gov for NCT02380677 2019: Zero new trials One trial updated to terminated |
|
MTL‐CEBPA (Mina Alpha) |
SMARTICLES (amphoteric liposomes) | Double stranded RNA | Advanced liver cancer and solid tumors |
2019: NCT02716012 (Ph I): Recruiting (Active as of 2021) 2021 additions: NCT04105335 (Ph I): Recruiting NCT04710641 (Ph II): Not yet recruiting |
2021: Two new trials One trial updated to active |
|
Imx‐110 (Immix Biopharma Australia) |
Micelle | Stat3/NF‐kB/poly‐tyrosine kinase inhibitor and low‐dose doxorubicin | Advanced solid tumors |
2019: NCT03382340 (Ph I/II): Recruiting |
2021: No updates |
|
IT‐141 (Intezyne Technologies) |
Micelle | SN‐38 | Advanced cancer |
2019: NCT03096340 (Ph I): Recruiting (terminated as of 2021) |
2021: One trial updated to terminated |
| Polymeric and micelles (other) | |||||
|
RadProtect (Original BioMedicals) |
PEG, iron, and amifostine micelle Transferrin‐mediated chelation for amifostine release |
Amifostine | Dose escalation and safety for acute radiation syndrome |
2016: NCT02587442 (Ph I): Unknown |
2021: No updates 2019: Zero new trials |
| Albumin‐bound (cancer) | |||||
|
ABI‐009 (Aadi with Celgene) |
Albumin‐bound drug nanoparticle | Rapamycin | Bladder cancer, PEComa, or pulmonary arterial hypertension |
2016: NCT02009332 (Ph I/II): Recruiting (Completed as of 2021) NCT02587325 (Ph I): Recruiting NCT02494570 (Ph II): Active not recruiting 2019 additions: NCT03747328 (Ph II): Not yet recruiting NCT03657420 (Ph I): Not yet recruiting (Withdrawn as of 2021) NCT03670030 (Ph II): Recruiting (Completed as of 2021) NCT03646240 (Ph I): Recruiting NCT03190174 (Ph I): Recruiting NCT00635284 (Ph I): Completed NCT03817515: Expanded Access Status: Available NCT03439462 (Ph II): Recruiting NCT03463265 (Ph II): Recruiting NCT03660930 (Ph I): Recruiting NCT02975882 (Ph I): Recruiting NCT02646319 (Ph I): Completed |
2021: Two trials updated to completed 2019: 12 new trials (two completed) |
|
ABI‐011 (NantBioScience) |
Albumin‐bound drug nanoparticle | Thiocolchicine analog (IDN 5405) | Solid tumors or lymphomas |
2016: NCT02582827 (Ph I): Recruiting (Withdrawn as of 2021 due to enrollment not initiated) |
2021: One trial updated to withdrawn 2019: Zero new trials |
| Inorganic (cancer) | |||||
|
AuroLase (Nanospectra Biosciences) |
PEG‐coated silica‐gold nanoshells | Thermal ablation from near infrared light stimulation | Thermal ablation of solid primary and/or metastatic lung tumors |
2016: NCT01679470: Terminated 2019 additions: NCT02680535: Recruiting (Completed as of 2021) NCT00848042: Completed 2021 additions: NCT04240639: Recruiting |
2021: One new trial One trial updated to completed Results posted and viewable on ClinicalTrials.gov for NCT00848042 2019: Two new trials One trial updated to terminated |
| Cornell Dots | Silica nanoparticles with a NIR fluorophore, PEG coating, and a 124I radiolabeled cRGDY targeting peptide | NIR fluorophore | Imaging of melanoma and malignant brain tumors |
2016: NCT01266096: Active, not recruiting 2019 additions: NCT03465618 (Ph I): Recruiting NCT02106598 (Ph II): Recruiting 2021 additions: NCT04167969 (Ph I): Recruiting |
2021: One new trial 2019: Two new trials |
| Magnablate | Iron nanoparticles | Iron | Thermal ablation for prostate cancer |
2016: NCT02033447 (Ph I): Completed |
2021: No updates 2019: Zero new trials One trial updated to completed |
|
NU‐0129 (Northwestern) |
Spherical nucleic acid platform consisting of nucleic acids arranged on the surface of a spherical gold nanoparticle | Nucleic acids | Glioblastoma |
2019: NCT03020017 (Ph I): Active, not recruiting (Completed as of 2021) |
2021: No updates |
| Imaging | |||||
|
AGuIX (National Cancer Institute, France) |
Polysiloxane gadolinium chelates based nanoparticles | Gadolinium chelates | Various cancers |
2019: NCT03308604 (Ph I): Recruiting (Unknown as of 2021) 2021 additions: NCT04881032 (Ph I/II): Not yet recruiting NCT03818386 (Ph II): Recruiting NCT04899908 (Ph II): Not yet recruiting NCT04094077 (Ph II): Active, not recruiting NCT04789486 (Ph I/II): Not yet recruiting NCT04784221 (Ph II): Not yet recruiting |
2021: Six new trials One trial updated to unknown status |
|
ONM‐100 (OncoNano Medicine) |
Micelle covalently conjugated to indocyanine green | Indocyanine green | Intraoperative detection of cancer |
2019: NCT03735680 (Ph II): Not yet recruiting (Recruiting as of 2021) |
2021: One trial updated to recruiting |